# Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects

> **NCT04686591** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 8 (actual)

## Conditions studied

- Cardiovascular Disease

## Interventions

- **DRUG:** AZD9977 capsule 50 mg
- **DRUG:** [14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)
- **DRUG:** [14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)

## Key facts

- **NCT ID:** NCT04686591
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-21
- **Primary completion:** 2021-02-04
- **Final completion:** 2021-02-04
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2021-03-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04686591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04686591, "Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04686591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*